Back

Azithromycin Plus Zinc Sulfate Rapidly and Synergistically Suppresses IκBα-Mediated In Vitro Human Airway Cell ACE2 Expression for SARS-CoV-2 Entry

Chen, Y.-K.; Huang, T.-T.; Chang, C.-W.; Lee, M.-C.; Lin, B.-R.; Lu, Y.-P.; Hsu, Y.-J.; Chuang, C.-Y.

2021-01-19 molecular biology
10.1101/2021.01.19.427206 bioRxiv
Show abstract

Large-scale efforts have been persistently undertaken for medical prophylaxis and treatment of COVID-19 disasters worldwide. A variety of novel viral spike protein-targeted vaccine preparations have recently been clinically distributed based on accelerated approval. We revisited the early but inconclusive clinical interest in the combination of azithromycin and zinc sulfate repurposing with safety advantages. In vitro proof of concept was provided for rapid and synergistic suppression of ACE2 expression following treatments in human airway cells, Calu-3 and H322M. The two representative ACE2-expressing human airway cells indicate the upper and lower respiratory tracts. Prophylactic and early therapeutic roles of azithromycin combined with zinc are proposed for virus cellular entry prevention potential bridging to effective antibody production.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
PLOS ONE
● 5266 papers in training set
Top 12%
15.3%
Similar papers in this journal
2
International Journal of Molecular Sciences
○ 494 papers in training set
Top 0.4%
8.0%
Similar papers in this journal
3
Biomolecules
○ 100 papers in training set
Top 0.1%
5.2%
Similar papers in this journal
4
Scientific Reports
○ 3612 papers in training set
Top 21%
4.4%
Similar papers in this journal
5
Biochemical and Biophysical Research Communications
○ 84 papers in training set
Top 0.2%
4.4%
Similar papers in this journal
6
Acta Biochimica et Biophysica Sinica
● 23 papers in training set
Top 0.1%
3.6%
7
Cells
○ 249 papers in training set
Top 0.9%
3.3%
8
Pharmaceuticals
○ 34 papers in training set
Top 0.2%
2.7%
9
Heliyon
○ 152 papers in training set
Top 2%
2.5%
10
Journal of Personalized Medicine
○ 28 papers in training set
Top 0.3%
2.0%
50% of probability mass above
11
Antioxidants
○ 25 papers in training set
Top 0.2%
2.0%
12
ACS Omega
● 105 papers in training set
Top 1%
1.8%
13
Metallomics
◐ 13 papers in training set
Top 0.1%
1.7%
14
Microorganisms
○ 106 papers in training set
Top 2%
1.5%
15
Frontiers in Molecular Biosciences
○ 102 papers in training set
Top 0.9%
1.5%
16
Nutrients
○ 67 papers in training set
Top 1%
1.5%
17
Molecules
○ 39 papers in training set
Top 0.8%
1.5%
18
Medical Research Archives
● 11 papers in training set
Top 0.2%
1.4%
19
Frontiers in Immunology
○ 638 papers in training set
Top 7%
1.1%
20
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 0.9%
1.1%
21
Biochimie
○ 25 papers in training set
Top 0.5%
1.1%
22
Pathogens
○ 56 papers in training set
Top 0.9%
1.1%
23
Biochemistry and Biophysics Reports
○ 30 papers in training set
Top 0.9%
1.1%
24
Frontiers in Pharmacology
○ 111 papers in training set
Top 2%
1.1%
25
Cell Cycle
○ 17 papers in training set
Top 0.3%
1.0%
26
FEBS Open Bio
○ 31 papers in training set
Top 0.8%
0.9%
27
ACS Chemical Neuroscience
● 67 papers in training set
Top 1%
0.9%
28
Molecular Biology Reports
○ 21 papers in training set
Top 0.8%
0.9%
29
Frontiers in Oncology
○ 103 papers in training set
Top 4%
0.6%
30
Molecular Neurobiology
○ 53 papers in training set
Top 1%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.